SYS-CON MEDIA Authors: Lori MacVittie, RealWire News Distribution, Cynthia Dunlop, Mark O'Neill, Kevin Benedict

News Feed Item

Appointments, Employee Option Grants, Clinical Data Presentations, New Launches, and Scheduled Financial Results - Research Report on Intuitive, Alexion, Sequenom, AcelRx, and Arrowhead

NEW YORK, December 16, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Intuitive Surgical, Inc. (NASDAQ: ISRG), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Arrowhead Research Corp. (NASDAQ: ARWR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Intuitive Surgical, Inc. Research Report  

On December 10, 2013, Intuitive Surgical, Inc. (Intuitive Surgical) reported that equity awards approved by the Compensation Committee of the Board of Directors, which consist entirely of Independent Directors, were distributed to 40 new employees. According to the Company, pursuant to NASDAQ Marketplace Rule 5635(c) (4), the equity awards were granted under the Intuitive Surgical 2009 Commencement Incentive Plan, which the Company's Board of Directors adopted for granting equity awards to new employees. Intuitive Surgical informed that 40 employees were granted options to purchase an aggregate of 19,132 shares of the Company's common stock, vested over four years and expire in 10 years assuming continued employment. According to the Company, the exercise price for the option shares was granted at $377.38, which was the closing price of the Company's common stock on the NASDAQ Global Market on December 6, 2013. According to Intuitive Surgical, the Company's policy is to issue stock option grants to new employees on the fifth business day of every calendar month. The Full Research Report on Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

Alexion Pharmaceuticals, Inc. Research Report

On December 8, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that researchers presented data from clinical trials demonstrating the clinical benefits of chronic Soliris (eculizumab) treatment in patients with atypical hemolytic uremic syndrome (aHUS), as well as new patient registry data, providing further insight into optimal care for patients with paroxysmal nocturnal hemoglobinuria (PNH) at the American Society of Hematology (ASH) 55th Annual Meeting and Exposition in New Orleans. According to the Company, Soliris is a first-in-class terminal complement inhibitor, specifically targets uncontrolled complement activation, and is the first and only approved treatment for patients with PNH, a debilitating, ultra-rare and life-threatening blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells). According to Alexion, Soliris is approved in nearly 50 countries for the treatment of PNH, including the United States, European Union and Japan. "Extensive clinical data presented at ASH demonstrate a significant and sustained inhibition of complement-mediated TMA with Soliris treatment and support the chronic use of Soliris in pediatric and adult patients with aHUS. New biomarker data also reinforce the need for chronic terminal complement inhibition in patients with aHUS and suggest that a loss of terminal complement inhibition could lead to a marked increase in thrombotic risk with the potential for sudden and catastrophic damage to vital organs," said Leonard Bell, M.D., CEO of Alexion. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

Sequenom Inc. Research Report  

On December 10, 2013, Sequenom Inc. (Sequenom) announced that Laboratoire Cerba has launched its validated noninvasive prenatal test (NIPT) to health care providers and their patients in France, Belgium, Luxembourg and portions of the Middle East and Africa. According to the Company, Laboratoire Cerba's test utilizes patented technology licensed from Sequenom to analyze the relative amounts of chromosomes 21, 18 and 13 in cell-free fetal DNA obtained from a maternal blood sample. "We are pleased to now offer prenatal testing through our network with the use of Sequenom's patented technology," said Sylvie Cado, Chief Operating Officer of Laboratoire Cerba. According to the Company, under the license from Sequenom, Laboratoire Cerba has the right to market its noninvasive test in multiple countries, including France, Luxembourg, Belgium, Lebanon, Morocco, Algeria, Tunisia, Libya, Senegal, Ivory Coast, Burkina Faso and Cameroun. The Full Research Report on Sequenom Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

AcelRx Pharmaceuticals, Inc. Research Report

On December 11, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx Pharmaceuticals) announced that Richard F. Afable, M.D, President and CEO of Covenant Health Network, was appointed to the Company's Board of Directors. "As CEO of an integrated healthcare delivery network that includes seven hospitals, Dr. Afable is at the forefront of changing how healthcare is delivered in the US.  We are delighted that Rick is going to be able to bring those insights to AcelRx," said Richard King, President and CEO of AcelRx Pharmaceuticals. According to the AcelRx Pharmaceuticals, Guy Nohra, Co-founder and Managing Director of Alta Partners, resigned from the Company's Board as of December 10, 2013. The Full Research Report on AcelRx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

Arrowhead Research Corp. Research Report  

On December 11, 2013, Arrowhead Research Corp. (Arrowhead Research) announced that it will report its financial results for Q4 FY 2013, and full-year FY 2013 (period ended September 30, 2013), on  Wednesday, December 18, 2013, at 4:30 p.m. ET. The Full Research Report on Arrowhead Research Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.